209 related articles for article (PubMed ID: 37541187)
1. Combined CRISPRi and proteomics screening reveal a cohesin-CTCF-bound allele contributing to increased expression of RUVBL1 and prostate cancer progression.
Tian Y; Dong D; Wang Z; Wu L; Park JY; ; Wei GH; Wang L
Am J Hum Genet; 2023 Aug; 110(8):1289-1303. PubMed ID: 37541187
[TBL] [Abstract][Full Text] [Related]
2. Combined CRISPRi and proteomics screening reveal a cohesin-CTCF-bound allele contributing to increased expression of
Tian Y; Dong D; Wang Z; Wu L; Park JY; Wei GH; Wang L;
bioRxiv; 2023 May; ():. PubMed ID: 36711639
[TBL] [Abstract][Full Text] [Related]
3. Functional genetic variants of RUVBL1 predict overall survival of Chinese patients with epithelial ovarian cancer.
Li H; Tong X; Xu Y; Wang M; Dai H; Shi T; Sun M; Chen K; Cheng X; Wei Q
Carcinogenesis; 2019 Oct; 40(10):1209-1219. PubMed ID: 31083717
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of regulatory SNPs that modulate transcription factor chromatin binding and gene expression in prostate cancer.
Jin HJ; Jung S; DebRoy AR; Davuluri RV
Oncotarget; 2016 Aug; 7(34):54616-54626. PubMed ID: 27409348
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic insights into genetic susceptibility to prostate cancer.
Tian P; Zhong M; Wei GH
Cancer Lett; 2021 Dec; 522():155-163. PubMed ID: 34560228
[TBL] [Abstract][Full Text] [Related]
6. CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer.
Ahmed M; Soares F; Xia JH; Yang Y; Li J; Guo H; Su P; Tian Y; Lee HJ; Wang M; Akhtar N; Houlahan KE; Bosch A; Zhou S; Mazrooei P; Hua JT; Chen S; Petricca J; Zeng Y; Davies A; Fraser M; Quigley DA; Feng FY; Boutros PC; Lupien M; Zoubeidi A; Wang L; Walsh MJ; Wang T; Ren S; Wei GH; He HH
Nat Commun; 2021 Mar; 12(1):1781. PubMed ID: 33741908
[TBL] [Abstract][Full Text] [Related]
7. Single-Nucleotide Polymorphisms Sequencing Identifies Candidate Functional Variants at Prostate Cancer Risk Loci.
Zhang P; Tillmans LS; Thibodeau SN; Wang L
Genes (Basel); 2019 Jul; 10(7):. PubMed ID: 31323811
[TBL] [Abstract][Full Text] [Related]
8. Post genome-wide association studies functional characterization of prostate cancer risk loci.
Jiang J; Cui W; Vongsangnak W; Hu G; Shen B
BMC Genomics; 2013; 14 Suppl 8(Suppl 8):S9. PubMed ID: 24564736
[TBL] [Abstract][Full Text] [Related]
9. CircMYO10 promotes osteosarcoma progression by regulating miR-370-3p/RUVBL1 axis to enhance the transcriptional activity of β-catenin/LEF1 complex via effects on chromatin remodeling.
Chen J; Liu G; Wu Y; Ma J; Wu H; Xie Z; Chen S; Yang Y; Wang S; Shen P; Fang Y; Fan S; Shen S; Fang X
Mol Cancer; 2019 Oct; 18(1):150. PubMed ID: 31665067
[TBL] [Abstract][Full Text] [Related]
10. Endometrial vezatin and its association with endometriosis risk.
Holdsworth-Carson SJ; Fung JN; Luong HT; Sapkota Y; Bowdler LM; Wallace L; Teh WT; Powell JE; Girling JE; Healey M; Montgomery GW; Rogers PA
Hum Reprod; 2016 May; 31(5):999-1013. PubMed ID: 27005890
[TBL] [Abstract][Full Text] [Related]
11. RUVBL1 promotes enzalutamide resistance of prostate tumors through the PLXNA1-CRAF-MAPK pathway.
Sun F; Wang X; Hu J; Liu J; Wang X; Jia W; Yu Z; Gao L; Dou B; Zhao R; Feng T; Wang X; Zhang W; Liu H; Liu K; Shao Y; Dong X; Han B
Oncogene; 2022 Jun; 41(23):3239-3250. PubMed ID: 35508542
[TBL] [Abstract][Full Text] [Related]
12. RUVBL1 is an amplified epigenetic factor promoting proliferation and inhibiting differentiation program in head and neck squamous cancers.
Lin D; Lin B; Bhanot H; Riou R; Abt NB; Rajagopal J; Saladi SV
Oral Oncol; 2020 Dec; 111():104930. PubMed ID: 32745900
[TBL] [Abstract][Full Text] [Related]
13. Liver haploinsufficiency of RuvBL1 causes hepatic insulin resistance and enhances hepatocellular carcinoma progression.
Mello T; Materozzi M; Zanieri F; Simeone I; Ceni E; Bereshchenko O; Polvani S; Tarocchi M; Marroncini G; Nerlov C; Guasti D; Bani D; Pinzani M; Galli A
Int J Cancer; 2020 Jun; 146(12):3410-3422. PubMed ID: 31721195
[TBL] [Abstract][Full Text] [Related]
14. Systematic enrichment analysis of potentially functional regions for 103 prostate cancer risk-associated loci.
Chen H; Yu H; Wang J; Zhang Z; Gao Z; Chen Z; Lu Y; Liu W; Jiang D; Zheng SL; Wei GH; Issacs WB; Feng J; Xu J
Prostate; 2015 Sep; 75(12):1264-76. PubMed ID: 26015065
[TBL] [Abstract][Full Text] [Related]
15. Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus.
Gao P; Xia JH; Sipeky C; Dong XM; Zhang Q; Yang Y; Zhang P; Cruz SP; Zhang K; Zhu J; Lee HM; Suleman S; Giannareas N; Liu S; ; Tammela TLJ; Auvinen A; Wang X; Huang Q; Wang L; Manninen A; Vaarala MH; Wang L; Schleutker J; Wei GH
Cell; 2018 Jul; 174(3):576-589.e18. PubMed ID: 30033361
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer risk SNP rs10993994 is a trans-eQTL for SNHG11 mediated through MSMB.
Bicak M; Wang X; Gao X; Xu X; Väänänen RM; Taimen P; Lilja H; Pettersson K; Klein RJ
Hum Mol Genet; 2020 Jun; 29(10):1581-1591. PubMed ID: 32065238
[TBL] [Abstract][Full Text] [Related]
17. Modifier locus mapping of a transgenic F2 mouse population identifies CCDC115 as a novel aggressive prostate cancer modifier gene in humans.
Winter JM; Curry NL; Gildea DM; Williams KA; Lee M; Hu Y; Crawford NPS
BMC Genomics; 2018 Jun; 19(1):450. PubMed ID: 29890952
[TBL] [Abstract][Full Text] [Related]
18. High-throughput screening of prostate cancer risk loci by single nucleotide polymorphisms sequencing.
Zhang P; Xia JH; Zhu J; Gao P; Tian YJ; Du M; Guo YC; Suleman S; Zhang Q; Kohli M; Tillmans LS; Thibodeau SN; French AJ; Cerhan JR; Wang LD; Wei GH; Wang L
Nat Commun; 2018 May; 9(1):2022. PubMed ID: 29789573
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival.
Li W; Middha M; Bicak M; Sjoberg DD; Vertosick E; Dahlin A; Häggström C; Hallmans G; Rönn AC; Stattin P; Melander O; Ulmert D; Lilja H; Klein RJ
Eur Urol; 2018 Dec; 74(6):710-719. PubMed ID: 30289108
[TBL] [Abstract][Full Text] [Related]
20. Validation of prostate cancer risk variants rs10993994 and rs7098889 by CRISPR/Cas9 mediated genome editing.
Wang X; Hayes JE; Xu X; Gao X; Mehta D; Lilja HG; Klein RJ
Gene; 2021 Feb; 768():145265. PubMed ID: 33122083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
